PARPi after PARPi in epithelial ovarian cancer.

Essel, K G; Behbakht, K; Lai, T; Hand, L; Evans, E; Dvorak, J; Ding, K; Konecny, G; Moore, K N

Essel, K G; Behbakht, K; Lai, T; Hand, L; Evans, E; Dvorak, J; Ding, K; Konecny, G; Moore, K N.

Affiliation

Essel KG; University of Oklahoma HSC, Oklahoma City, OK, United States.
Behbakht K; University of Colorado School of Medicine, Denver, CO, United States.
Lai T; University of California Los Angeles, Los Angeles, CA, United States.
Hand L; University of Pittsburgh, Pittsburgh, PA, United States.
Evans E; University of Oklahoma HSC, Oklahoma City, OK, United States.
Dvorak J; University of Oklahoma HSC, Oklahoma City, OK, United States.
Ding K; University of Oklahoma HSC, Oklahoma City, OK, United States.
Konecny G; University of California Los Angeles, Los Angeles, CA, United States.
Moore KN; The University of Oklahoma, Stephenson Cancer Center, Oklahoma City, OK, United States.

Gynecol Oncol Rep ; 35: 100699, 2021 Feb.

Article de En | MEDLINE | ID: mdl-33537389

Mots clés

Ovarian cancer; PARP inhibitor

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Prognostic_studies Langue: En Journal: Gynecol Oncol Rep Année: 2021 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Pays-Bas

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google